205 results on '"Tickoo, Satish K"'
Search Results
2. Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations
3. Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors
4. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification
5. Contributing Authors
6. Contributing Authors
7. Supplementary Figure 3 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
8. Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
9. Supplementary Figure 2 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
10. Supplementary Figure 4 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
11. Supplementary Figure 5 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
12. Supplementary Authors' List from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
13. Supplementary Figure 1 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
14. Data from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
15. Supplementary Tables 1-2 from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
16. Supplementary Tables 1-2 from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
17. Data from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
18. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
19. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
20. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
21. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
22. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis
23. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy
24. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series
25. An introduction to the WHO 5th edition 2022 classification of testicular tumours
26. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma
27. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
28. Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome
29. Kidney
30. Preface
31. Adult Wilms Tumor
32. CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract
33. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas
34. Developmental chromatin programs determine oncogenic competence in melanoma
35. MP39-16 REGULATORY T CELL GENE SIGNATURES IN SARCOMATOID RENAL CELL CARCINOMA
36. MP39-09 GENOMIC CHARACTERIZATION OF AGGRESSIVE SPORADIC EPITHELIOID ANGIOMYOLIPOMA
37. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma
38. Clinical utility of subclassifying positive surgical margins at radical prostatectomy
39. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
40. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course
41. Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma
42. Testis and Paratestis Including Spermatic Cord
43. Contributors
44. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor
45. Sarcomatoid renal cell carcinoma: biology, natural history and management
46. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors
47. Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
48. Developmental chromatin programs determine oncogenic competence in melanoma
49. PD39-10 LONG-TERM SURVIVORS WITH SARCOMATOID RENAL CELL CARCINOMA
50. Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.